SCIENTISTS AND STUDY PARTICIPANTS GATHER AT CONFERENCE ON SCIENTIFIC CONTRIBUTIONS OF THE WOMEN'S HEALTH INITIATIVE -- THE LARGEST STUDY OF OLDER WOMEN'S HEALTH

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



U.S. Department of Health and Human Services 
NATIONAL INSTITUTES OF HEALTH 
NIH News 
National Heart, Lung, and Blood Institute (NHLBI)
http://www.nhlbi.nih.gov/

FOR IMMEDIATE RELEASE: Wednesday, February 22, 2006

CONTACT: NHLBI Communications Office, 301-496-4236,
nhlbi_news@xxxxxxxxxxxxx

Sessions on Study Results, Ongoing Extension Study, and Future Research
SCIENTISTS AND STUDY PARTICIPANTS GATHER AT CONFERENCE ON SCIENTIFIC
CONTRIBUTIONS OF THE WOMEN'S HEALTH INITIATIVE -- THE LARGEST STUDY OF
OLDER WOMEN'S HEALTH

Many of the nation's leading scientists and experts on women's health
will join Women's Health Initiative (WHI) study participants February 28
-- March 1, 2006 at the National Institutes of Health (NIH) campus in
Bethesda, MD to celebrate the legacy and probe the findings and future
directions of the WHI. The WHI is the largest and most comprehensive
study of postmenopausal women's health ever conducted in the United
States. From revealing the effects of a low-fat diet and calcium/vitamin
D supplements to the dangers of hormone replacement therapy, the study
has helped to shape and advance the health care of women for more than a
decade.

Conference speakers will closely examine findings from the WHI's
clinical trials and observational studies, analyze the study's impact on
public health and on national guidelines and recommendations, and
discuss not only the ongoing extension study but also future research
using stored blood and genetic samples.

Presenters include Elias A. Zerhouni, M.D., director of the NIH;
Elizabeth G. Nabel, M.D., director of the National Heart, Lung, and
Blood Institute (NHLBI), which funded the study, and also current
director of the WHI; Vivian Pinn, M.D., director of the Office of
Research on Women's Health; Bernadine Healy, M.D., who launched the
study as the head of NIH in 1991 and Marcia Stefanick, Ph.D., chair of
the WHI Steering Committee and principal investigator at the Stanford
University clinical center study site. Most of the WHI principal
investigators will be presenting at or attending the event. In addition,
participants in each of the three clinical trials will share personal
accounts of their involvement in the historic study.

"The WHI has replaced conventional wisdom about women's health issues
with evidence-based research findings, and reminded us that there aren't
always simple, universal answers to complex questions. It also
influenced the ways in which scientific studies involving women are now
designed and conducted," said Dr. Zerhouni. "These are just a few of the
many contributions from a study that will continue to enhance the lives
of women for decades to come."

"The WHI has significantly contributed to our knowledge of disease
prevention in postmenopausal women and has challenged many clinical
practice and prevention policies," said Dr. Nabel, "Due to the
dedication of thousands of women and the widespread release of study
findings, the WHI has had a global impact on women's health care and on
the lives of generations of mothers, daughters, and granddaughters."

Highlights of the two day conference include:

-- Presentations on the design, implications, and primary results of the
recently published Dietary Modification Trial. Speakers include WHI
consultant Leslie Ford, M.D., Associate Director of the National Cancer
Institute's Division of Cancer Prevention, and WHI principal
investigator Ross Prentice, Ph.D., of the Fred Hutchison Cancer Research
Center in Seattle. The Dietary Modification trial is the largest-ever
clinical trial of a low-fat diet. The study revealed that following an
eating pattern lower in total fat did not significantly reduce the risk
of breast cancer, heart disease, stroke, or colorectal cancer in healthy
postmenopausal women.

-- Sessions on the public health impact and results of the WHI Calcium
and Vitamin D trial. Speakers include: WHI consultant Joan McGowan,
Ph.D., Director of the Musculoskeletal Diseases Branch at the National
Institute of Arthritis and Musculoskeletal and Skin Diseases; Rebecca
Jackson and Jean Wactawski-Wende, Ph.D., WHI principal investigator at
the University at Buffalo. Released this month, results from the trial
revealed that calcium and vitamin D supplements in postmenopausal women
have a modest benefit on bone mineral density and prevent hip fractures
in certain groups but do not prevent colorectal cancer or other
fractures.

-- Sessions on the results and public health impact of the WHI hormone
trials and future directors for menopausal hormone research. Speakers
include Dr. Stefanick, Barbara Alving, M.D., former director of the WHI,
and Jacques Rossouw, M.D., WHI Project Officer. The long-term WHI
hormone studies evaluated the effects of menopausal hormone therapy on
heart disease, breast cancer, colorectal cancer, and osteoporosis. In
2002, the WHI estrogen-plus-progestin study was stopped because of an
increased risk of breast cancer and because, overall, risks from use of
the hormones outweighed the benefits. The combination therapy increased
the risk for heart attack, stroke, and blood clots but also reduced the
risk for hip and other fractures, and colorectal cancer. The study
results reverberated throughout the world and significantly changed the
treatment of postmenopausal women. Two years later, the WHI
estrogen-alone study was halted because of an increased risk of stroke
and no significant effect on the risk of heart disease. Estrogen-alone
also increased the risk for venous thrombosis (blood clots deep in a
vein). Like the combination therapy, estrogen-alone reduced the risk for
hip and other fractures.

-- Sessions on the WHI Extension Study, the impact of WHI on national
guidelines and recommendations, and directions for future research on
women's health. Speakers include Richard Hodes, M.D., director of the
National Institute on Aging; Dr. Nabel, Dr. Pinn, Marian Limacher, M.D.
WHI investigator at the University of Florida in Gainesville, and Sally
Shumaker, Ph.D. of Wake Forest University School of Medicine and
principal investigator of the Women's Health Initiative Memory Study.
The WHI Extension Study will follow WHI participants through 2010 and
will allow for the collection of longer-term data on the effects of
stopping hormones (or making other health changes) on women's health.

-- Sessions on the WHI observational study. Speakers include Teri
Manolio, M.D. of NHLBI and the National Human Genome Research Institute,
WHI investigator JoAnn Manson, M.D., DrPH of the Harvard School of
Public Health and WHI investigator Sylvia Wassertheil-Smoller, Ph.D. of
the Albert Einstein College of Medicine in New York City. The
observational study yielded important findings on the effects of
exercise on cardiovascular disease, breast cancer, and diabetes,
including that the duration of exercise increases the degree of
protection against disease, and walking is as effective as more vigorous
exercise in protecting against breast cancer. 

Immediately before the conference, scientists from around the country
will discuss proposed studies using WHI blood and DNA samples to
determine the factors that contribute to an increased risk of
cardiovascular disease, cancer, and fractures in women. WHI
investigators are already engaged in a separate genome association
study, which will examine the DNA of some 12,000 participants with and
without heart disease, stroke, and breast cancer, to determine the genes
that predict these diseases.

For more information on the WHI: A Legacy To Future Generations
conference and for an agenda, please visit,
http://www.nhlbi.nih.gov/whi/references.htm. For more information on the
Women's Health Initiative, see http://www.nhlbi.nih.gov/whi. Reporters
can pre-register for the conference or schedule interviews with speakers
and participants by calling the NHLBI Communications Office at
301-496-4236 or e-mailing nhlbi_news@xxxxxxxxxxxxxx Room J in the
Natcher Auditorium on the NIH Campus will be available for press use and
registration, and will feature a video feed of the conference
proceedings.

NHLBI is part of the National Institutes of Health (NIH), the Federal
Government's primary agency for biomedical and behavioral research. NIH
is a component of the U.S. Department of Health and Human Services.
NHLBI press releases and other materials including information about
women and heart disease are available online at www.nhlbi.nih.gov. 

The National Institutes of Health (NIH) -- "The Nation's Medical
Research Agency" -- includes 27 Institutes and Centers and is a
component of the U. S. Department of Health and Human Services. It is
the primary Federal agency for conducting and supporting basic,
clinical, and translational medical research, and it investigates the
causes, treatments, and cures for both common and rare diseases. For
more information about NIH and its programs, visit http://www.nih.gov.
  
##
 
This NIH News Release is available online at:
http://www.nih.gov/news/pr/feb2006/nhlbi-22.htm.

To subscribe (or unsubscribe) from this list, go to
http://list.nih.gov/cgi-bin/wa?SUBED1=nihpress&A=1.

[Index of Archives]     [CDC News]     [FDA News]     [USDA News]     [Yosemite News]     [Steve's Art]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux